TNFSF10 and neoplasm: We next wanted to explore how less TRAIL-sensitive tumor lines, LN229[25] and U87,[26] respond to bioprinted NHF1TRAIL therapy, and how this treatment compares to media conditioned by plated NHF1TRAIL cells.